

Inconclusive Evidence for or against Positive Antigen Selection in the Shaping of Human Immunoglobulin E Repertoires: A Call for New Approaches

Mattias Levin · Mats Ohlin

Department of Immunotechnology, Lund University, Lund, Sweden

Key Words

Allergen · Immunoglobulin E · Mutation · Repertoire · Selection

Abstract

Background: The mechanisms driving the development of immunoglobulin E (IgE) antibody repertoires are a matter of debate. Alternatives to the classical view on antibody development, involving somatic mutation and antigen-driven selection of high-affinity variants in germinal centers, have been proposed. **Methods:** We have re-analyzed the pattern of mutations in previously isolated and characterized human clonally unrelated IgE-encoding transcripts using the validated focused binomial methodology to find evidence in such genes of antigen-specific selection. **Results:** As expected there is a selection against replacement mutations in IgE framework regions. In contrast, in all examined cases but one (assessing IgE repertoires of parasite-infected individuals) there was no evidence in favor of either positive or negative selection in complementarity determining regions. Importantly, however, the validated method also failed to detect selection for replacement mutations in two, non-IgE, hypermutated antibody populations targeting tetanus toxoid and vaccinia virus, respectively. **Conclusions:** Current methodology is unable to define with certainty, using commonly as-

sessed IgE repertoire sizes, whether antigen selection is or is not a major driving force in the establishment of human IgE. New approaches are needed to address this matter.

Copyright © 2013 S. Karger AG, Basel

Introduction

Antibodies of the immunoglobulin E (IgE) isotype are well-described, key components of the defense against parasites and also of type 1-hypersensitivity reactions. The mechanisms behind the development of diversity in IgE antibody repertoires, however, are a matter of substantial debate. The classical view of development of hypermutated antibodies is that selection of B cells producing such antibodies occurs in germinal centers. To ensure development towards a high affinity antibody this process is believed to favor replacement mutations targeting the complementarity determining regions (CDR) rather than silent mutations. In contrast, replacement mutations are counter-selected in the framework regions (FR), as they are likely to be accompanied by unacceptable structural effects on the folded protein. The end product of this antigen selection process should be a pool of B cells carrying genes encoding antigen-specific, high-affinity antibodies. However, in the case of IgE-repertoire develop-

ment, alternative mechanisms have been proposed, not necessarily involving selection by antigen [1]. For instance, extensive polyclonal expansion of B cells producing IgE has been suggested to be a major contributor to the establishment of such antibodies [1, 2]. Microbial toxins might act as superantigens, exhibiting excessive polyclonal mitogenic activity on B cell populations. Such repertoires may be dominated by sequences that carry a lower than expected number of substitutions in the CDR as there will be no selective advantage in creating an optimal binding site towards a conventional antigen. Indeed, some [2–5] but not all [6] studies have indicated evidence of mutations in IgE not compatible with selection by antigens.

What then is the basis for the differences between different studies of the involvement of selection in the shaping of IgE repertoires? Firstly, the studies have assessed IgE in different clinical conditions and it is not unreasonable to expect that IgE develop in different ways in different diseases. Secondly, the analytical approach is a source of error. Identification of antigen-directed selection in antibody evolution is problematic for a number of reasons including, but not limited to, high background of neutral mutations, different codon usage in different parts of antibody sequences and differences in the mutagen ability of different codons [7–11]. Furthermore, unequivocal assignment of germline gene origin is difficult as there is generally no knowledge of the germline gene repertoire that generated the IgE repertoires. Consequently misassignment has probably occurred in several cases, adding irrelevant noise to the data set.

To minimize the influence of methodological differences we have now re-assessed the pattern of mutations in several IgE-encoding gene populations using a single, extensively validated methodology [10–12] to define whether or not it is possible to pin-point antigen selection as a major driving force shaping the development of IgE repertoires as they are described in today's literature.

Materials and Methods

Study Material

Antibody heavy chain variable domain-encoding sequences (table 1; online suppl. table 1; for all online suppl. material, see www.karger.com/doi/10.1159/000345421) were derived from IgE-producing cells found in peripheral blood of patients diagnosed with allergic rhinitis [13, 14] and in sinus mucosa of patients diagnosed with chronic rhinosinusitis or non-allergic fungal eosinophilic sinusitis [15], the latter being a condition devoid of systemic allergy but with signs of local reactions similar to allergic inflammation. We also included sequences encoding IgE derived

Table 1. Characteristics of investigated antibody repertoires

Donor condition	Lymphocyte source	Iso-type	Do-nors n	Analyzed IGHV sequences n	IGHV germline ¹ n	Frequency of mutations in IGHV gene, %	Focused binomial test p value ²		Corrected focused binomial test p value ^{2,3}		Reference No.
							CDR	FR	CDR	FR	
Chronic rhinosinusitis	sinus mucosa	IgE	4	24	4	6.1	0.16	-2.4×10^{-7}	0.19	-4.8×10^{-7}	15
Non-allergic fungal eosinophilic sinusitis	sinus mucosa	IgE	4	34	4	6.6	0.37	-1.2×10^{-14}	0.40	-2.8×10^{-14}	15
Seasonal allergic rhinitis	peripheral blood	IgE	2	70	5	5.6	0.056	-6.4×10^{-20}	0.087	-1.8×10^{-19}	13
Allergic asthma (children)	peripheral blood	IgE	13	102	5	6.8	-0.11	-7.4×10^{-25}	-0.14	-5.2×10^{-24}	6
Parasitized	peripheral blood	IgE	14	53	6	8.4	-0.015	-8.3×10^{-29}	-0.026	-1.2×10^{-27}	5
Immunized with tetanus toxoid	peripheral blood	IgG ⁴	2	57	5	8.2	-0.42	-4.4×10^{-20}	-0.42	-1.5×10^{-19}	16
Immunized with vaccinia virus	peripheral blood	IgG ⁴	5	85	7	7.6	0.081	-1.1×10^{-20}	0.11	-5.1×10^{-20}	17

¹ In addition, several different allelic variants of these germline genes were used in some repertoires.

² Test was performed as described by Uduman et al. [12]. Positive and negative p values suggest positive and negative selection, respectively. Repertoires showing significant evidence for selection are shaded in grey.

³ Corrected for the influence of multiple comparisons using the Benjamini–Hochberg false discovery method.

⁴ The isotype of this repertoire was not described in detail. However, the 3'-primer used for amplification of the heavy chain variable domain-encoding genes shows perfect match with sequences encoding IgG but 11, 8, 7 and 3 mismatches with sequences encoding IgM, IgA, IgD and IgE, respectively. Furthermore, transcripts encoding IgE are likely to be very rare in this material. Altogether this suggests that the majority of isolated genes encoded IgG.

from children with allergic asthma [6] and parasitized subjects [5] in this study. In addition, two repertoires of antibodies, likely mostly IgG, specific for tetanus toxoid and vaccinia virus of recently boosted individuals were included for comparison [16, 17].

Analysis

To avoid repeated analysis of frequently occurring rearrangements, only one randomly picked sequence of the different clonotypes [a clonotype is defined as described by the authors or as a set of clones with an origin in a given rearrangement (with an origin in a common IGHV gene and a nucleotide identity within the heavy chain CDR3 of >80%) that has occurred in a single individual] was used in the study. To be included, a sequence from each clonotype must also be accessible from GenBank. The sequence must furthermore be complete across the investigated sequence, must not show evidence (as assessed by the V-QUEST algorithm [18]) of mutations involving insertions or deletions, and must not contain unspecified bases. The IGHV gene/allele that had been used in the process that generated a rearranged heavy-chain encoding sequence was defined using the IMGT/V-QUEST online tool [18]. As PCR had been used to amplify sequences, bases comprising the first codons were not included in the analysis in order to avoid an influence of primer design on the assignment of germline gene origin and mutation. Consequently, codons 1–8 were always excluded and, in the case of sequences described by Kerzel et al. [6], codons 1–26 were excluded. All these gene populations represent diverse sets of sequences in terms of V gene subgroup and gene usage (table 1). All sets also carry high frequencies of mutations at the nucleotide level (table 1).

The analysis of selection was performed using the extensively validated focused binomial test (<http://clip.med.yale.edu/sel/>) as described by Hershberg et al. [11] and as modified by Uduman et al. [12]. We used the default setting of the online tool, i.e. CDR were defined as codons 27–38 and 56–65 in accordance with the unique IMGT CDR definition rules and the IMGT numbering system [19]. These residues create a surface directed towards an antigen sitting in a binding site and avoid analysis of residues in the C' β -strand of the folded heavy chain variable domain as included in the Kabat definition of the second heavy chain CDR. Codons beyond residue 104 were not included in the analysis to eliminate confounding effects caused by sequence alterations associated with VDJ rearrangement process, i.e. modifications that are unrelated to the somatic hypermutation and the selection process. The Benjamini-Hochberg false discovery method was employed, using an on-line tool (<http://sdmproject.com/utilities/?show=FDR>) to correct for the fact that multiple statistical tests were performed.

Results and Discussion

In agreement with prior studies of mutated immunoglobulin sequences [5, 7], the vast majority of sequences did not show statistically significant evidence of positive or negative selection on their own (data not shown). All populations showed strong negative selection against mutations in immunoglobulin FR (table 1), in agreement with expectations (assuming that many mutations in FR

will detrimentally influence the stability of the V domains) and past experience [10]. Furthermore, there was little evidence of positive selection in the CDR of IgE-encoding sequence populations. Only IgE derived from parasitized individuals [5] showed statistically significant selection in CDR, in this case negative selection. This is in agreement with past studies of this population of sequences that showed less evidence of antigen selection as compared to IgG [5]. The study by Kerzel et al. [6], which involved sequencing of more than 1,000 IgE-encoding genes from 13 lymphocyte donors, has previously reported evidence of antigen selection in IgE. That repertoire, however, did not show evidence of positive selection as assessed using the focused binomial test. Importantly though, the tetanus toxoid-specific and the vaccinia virus-specific antibody populations also did not show evidence of positive selection in CDR using the focused binomial test system. This finding suggests that an extensively validated analytical approach like the one employed in this study cannot with ease detect positive selection in human antibody populations highly suspected to have undergone positive selection. This points to the limitation of the approach itself. It has previously even been suggested that none of the frequently used tests, approaches such as the binomial test [8], the multinomial test [20] or the focused binomial test [11], are able to detect selection by antigen in the CDR of immunoglobulin-encoding transcripts [10]. This highlights the complexity of designing such algorithms with high enough specificity without reducing sensitivity to levels where selection is very difficult to detect. The lack of selection was not accompanied by a low level of mutation in the sequences used for analysis as the frequency of mutation was 5.6–8.4% (table 1). Thus, sample sizes like those used in this study, a size common to most studies of IgE-encoding gene sequences, are likely insufficient to establish evidence of positive selection in CDR using those tests available today.

The failure to detect evidence for positive selection in sets of antibody-encoding genes of sizes common to many studies of IgE repertoires suggests that new approaches need to be taken to address this issue. One has to realize that it is by no means certain that antigen selection translates into a mathematically detectable enhancement of substitutions in CDR. Indeed, many affinity-enhancing mutations do not reside in CDR [21], a fact that confounds this analytical approach. It has also been argued that false-positive results are frequent, in particular when not applying an analytical strategy based on a focused binomial methodology and, even more damaging,

that one should not even expect to find mathematically detectable signs of selection in the CDR of antigen-binding sites of antibodies [10].

If we ever are going to be able to detect subtle increases in substitution in CDR as a consequence of antigen selection, a problem is that even rather extensive conventional sequencing efforts (exemplified by Kerzel et al. [6]) generate a relatively small number of independent clones due to the oligoclonal nature of IgE repertoires [13]. It is expected that larger, carefully controlled studies to clarify the existence, or not, of positive and negative selective pressure during the development of the different human IgE repertoires will be required to resolve this matter. It is anticipated that high throughput sequencing of genes derived from large numbers of donors may aid in this endeavor. Firstly, such methodology provides larger data sets that may be required to resolve this matter with statistical significance. Secondly, the methodology can be used to deduce the germline repertoire of each individual [22], thereby facilitating correct germline gene assignments eliminating background noise in the data set. It is anticipated that such efforts may eventually permit us to address this matter.

Ultimately the resolution of the matter of whether or not selection for higher affinity occurs in human IgE may have to await a very laborious analysis of mutated, allergen-specific IgE clones in comparison to their unmutated germline counterparts. Current technology has, as far as we are aware, not been able to identify gene sequences encoding native combinations of heavy and light chain variable domains of IgE with known allergen specificity, for instance through sorting of cells of the B cell lineage by flow cytometry in combination with cloning of the corresponding variable domain-encoding genes. Such

technology in combination with determination of the affinity for the immunizing agent has in the past been used to decipher the extent of affinity maturation in the much more commonly occurring cells of the B cell lineage that encode isotypes other than IgE [16]. However, even when access to such human IgE-producing clones can be ensured in the future, many IgE responses pose a very specific problem in the context of analysis of affinity maturation. Many allergens have cross-reacting counterparts in other species or are even represented by a multitude of more or less similar isoallergens and isoforms within a given species [23]. In most cases it will likely be impossible to know the allergen form(s) that originally induced the response and that was/were the driver in the affinity maturation process that eventually resulted in the population of IgE-producing B cells observed in a given allergic individual. Consequently it will likely be very difficult to define with certainty the extent of affinity maturation that has occurred in vivo unless one is able to assess a response involving few cross-reacting allergens/allergen isoforms or a response focused on a conserved epitope. Until these conceptual matters have been resolved and given the inability of even a highly validated statistical methodology to detect positive selection in IgG-encoding antibody populations, we suggest that claims of the presence or lack of selection in IgE responses, and its relation to the mechanism of IgE-mediated disease, have to be treated with caution.

Acknowledgements

This study was supported by grants from the Swedish Research Council (grant numbers: 521-2008-3614 and 521-2011-3282) and Alfred Österlunds Stiftelse.

References

- 1 Gould HJ, Takhar P, Harries HE, Chevetton E, Sutton BJ: The allergic march from *Staphylococcus aureus* superantigens to immunoglobulin E. *Chem Immunol Allergy* 2007;93: 106–136.
- 2 Coker HA, Harries HE, Banfield GK, Carr VA, Durham SR, Chevetton E, Hobby P, Sutton BJ, Gould HJ: Biased use of VH5 IgE-positive B cells in the nasal mucosa in allergic rhinitis. *J Allergy Clin Immunol* 2005; 116:445–452.
- 3 Dahlke I, Nott DJ, Ruhno J, Sewell WA, Collins AM: Antigen selection in the IgE response of allergic and nonallergic individuals. *J Allergy Clin Immunol* 2005;117:1477–1483.
- 4 Pratt E, Collins AM, Sewell WA, Harvey RJ: Antigen selection in IgE antibodies from individuals with chronic rhinosinusitis with nasal polyps. *Am J Rhinol Allergy* 2010; 24:416–421.
- 5 Wang Y, Jackson KJL, Chen Z, Gaeta BA, Siba PM, Pomat W, Walpole E, Rimmer J, Sewell WA, Collins AM: IgE sequences in individuals living in an area of endemic parasitism show little mutational evidence of antigen selection. *Scand J Immunol* 2011;73: 496–504.
- 6 Kerzel S, Rogosch T, Struecker B, Maier RF, Zemlin M: IgE transcripts in the circulation of allergic children reflect a classical antigen-driven B cell response and not a superantigen-like activation. *J Immunol* 2010; 185:2253–2260.
- 7 Bose B, Sinha S: Problems in using statistical analysis of replacement and silent mutations in antibody genes for determining antigen-driven affinity selection. *Immunology* 2005; 116:172–183.
- 8 Chang B, Casali P: The CDR1 sequences of a major proportion of human germline Ig VH genes are inherently susceptible to amino acid replacement. *Immunol Today* 1994;15: 367–373.

- 9 Dunn-Walters DK, Spencer J: Strong intrinsic biases towards mutation and conservation of bases in human IgVH genes during somatic hypermutation prevent statistical analysis of antigen selection. *Immunology* 1998;95:339–345.
- 10 MacDonald CM, Boursier L, D'Cruz DP, Dunn-Walters DK, Spencer J: Mathematical analysis of antigen selection in somatically mutated immunoglobulin genes associated with autoimmunity. *Lupus* 2010;19:1161–1170.
- 11 Hershberg U, Uduman M, Shlomchik MJ, Kleinstein SH: Improved methods for detecting selection by mutation analysis of Ig V region sequences. *Int Immunol* 2008;20:683–694.
- 12 Uduman M, Yaari G, Hershberg U, Stern JA, Shlomchik MJ, Kleinstein SH: Detecting selection in immunoglobulin sequences. *Nucleic Acids Res* 2011;39:W499–W504.
- 13 Andréasson U, Flicker S, Lindstedt M, Valenta R, Greiff L, Korsgren M, Borrebaeck CAK, Ohlin M: The human IgE-encoding transcriptome to assess antibody repertoires and repertoire evolution. *J Mol Biol* 2006;362:212–227.
- 14 Persson H, Karbalaie Sadegh M, Greiff L, Ohlin M: Delineating the specificity of an IgE-encoding transcriptome. *J Allergy Clin Immunol* 2007;120:1186–1192.
- 15 Levin M, Tan LW, Baker L, Wormald PJ, Greiff L, Ohlin M: Diversity of IgE-encoding transcripts in sinus mucosa of subjects diagnosed with non-allergic fungal eosinophilic sinusitis. *Clin Exp Allergy* 2011;41:811–820.
- 16 Poulsen TR, Meijer PJ, Jensen A, Nielsen LS, Andersen PS: Kinetic, affinity and diversity limits of human polyclonal antibody responses against tetanus toxoid. *J Immunol* 2007;179:3841–3850.
- 17 Lantto J, Haahr Hansen M, Rasmussen SK, Steinaa L, Poulsen TR, Duggan J, Dennis M, Naylor I, Easterbrook L, Bregenholt S, Haurum J, Jensen A: Capturing the natural diversity of the human antibody response against vaccinia virus. *J Virol* 2011;85:1820–1833.
- 18 Brochet X, LeFranc MP, Giudicelli V: IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. *Nucl Acids Res* 2008;36:W503–W508.
- 19 Lefranc MP, Pommié C, Ruiz M, Giudicelli V, Foulquier E, Truong L, Thouvenin-Contet V, Lefranc G: IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. *Dev Comp Immunol* 2003;27:55–77.
- 20 Lossos IS, Tibshirani R, Narasimhan N, Levy R: The interference of antigen selection on Ig genes. *J Immunol* 2000;165:5122–5126.
- 21 Daugherty PS, Chen G, Iverson BL, Georgiou G: Quantitative analysis of the effect of the mutation frequency on the affinity maturation of single chain Fv antibodies. *Proc Natl Acad Sci USA* 2000;97:2029–2034.
- 22 Boyd SD, Gaëta BA, Jackson KJ, Fire AZ, Marshall EL, Merker JD, Maniar JM, Zhang LN, Sahaf B, Jones CD, Simen BB, Hanczark B, Nguyen KD, Nadeau KC, Egholm M, Miklos DB, Zehnder JL, Collins AM: Individual variation in the germline Ig gene repertoire inferred from variable region gene rearrangements. *J Immunol* 2010;184:6986–6992.
- 23 Chapman MD: Allergen nomenclature. *Clin Allergy Immunol* 2008;21:47–58.

Supplementary Table 1. GenBank accession numbers of immunoglobulin gene sequences investigated in this study.

Donor condition	GenBank accession numbers	Reference
Chronic rhinosinusitis	HQ703971, HQ703972, HQ703973, HQ703976, HQ703981, HQ703982, HQ703985, HQ703986, HQ703991, HQ703992, HQ703993, HQ703994, HQ703995, HQ703996, HQ703997, HQ703999, HQ704000, HQ704001, HQ704002, HQ704003, HQ704004, HQ704005, HQ704006, HQ704008	15
Non-allergic fungal eosinophilic sinusitis	HQ704013, HQ704014, HQ704015, HQ704016, HQ704017, HQ704018, HQ704021, HQ704023, HQ704026, HQ704027, HQ704028, HQ704029, HQ704030, HQ704035, HQ704037, HQ704038, HQ704039, HQ704041, HQ704042, HQ704043, HQ704044, HQ704046, HQ704047, HQ704048, HQ704049, HQ704050, HQ704052, HQ704054, HQ704055, HQ704056, HQ704057, HQ704058, HQ704063, HQ704065	
Seasonal allergic rhinitis	DQ065615, DQ065616, DQ065617, DQ065618, DQ065620, DQ065621, DQ065623, DQ065624, DQ065625, DQ065626, DQ065628, DQ065629, DQ065630, DQ065631, DQ065632, DQ065633, DQ065634, DQ065636, DQ065637, DQ065638, DQ065639, DQ065640, DQ065642, DQ065643, DQ065644, DQ065646, DQ065650, DQ065651, DQ065654, DQ065656, DQ065657, DQ065659, DQ065660, DQ065661, DQ065662, DQ065663, DQ065664, DQ065666, DQ065667, DQ065668, DQ065669, DQ065670, DQ065672, DQ065673, DQ065674, DQ065675, DQ065676, DQ065677, DQ065681, DQ065683, DQ065684, DQ065687, DQ065690, DQ065692, DQ065696, DQ065697, DQ065698, DQ065700, DQ065702, DQ065704, DQ065705, DQ065707, DQ065708, DQ065713, DQ065715, DQ065716, DQ065718, DQ065720, DQ065722, DQ065726	13
Allergic asthma (children)	FJ839984, FJ840099, FJ840266, FJ840328, FJ840238, FJ839980, FJ840053, FJ840143, FJ840239, FJ840204, FJ840113, FJ840016, FJ840344, FJ840306, FJ840332, FJ840407, FJ840373, FJ840153, FJ840209, FJ840349, FJ840355, FJ840317, FJ840265, FJ840006, FJ840399, FJ840151, FJ840335, FJ840060, FJ840237, FJ840149, FJ840330, FJ840274, FJ840370, FJ840331, FJ840338, FJ840337, FJ840320, FJ840319, FJ840386, FJ840380, FJ840083, FJ839989, FJ840195, FJ840198, FJ840175, FJ840120, FJ840061, FJ840310, FJ840268, FJ840371, FJ840069, FJ840362, FJ840324, FJ840336, FJ840439, FJ840366, FJ840322, FJ840240, FJ840303, FJ840305, FJ840128, FJ840321, FJ840398, FJ840138, FJ840345, FJ840352, FJ840374, FJ840315, FJ840408, FJ839993, FJ839992, FJ840087, FJ840211, FJ840097, FJ840028, FJ840075, FJ840375, FJ840418, FJ840302, FJ840055, FJ840431, FJ840042, FJ840065, FJ840212, FJ840243, FJ840270, FJ840089, FJ839988, FJ840369, FJ840168, FJ840269, FJ840435, FJ840161, FJ840363, FJ840360, FJ840144, FJ840293, FJ840287, FJ840267, FJ840010, FJ840227, FJ840379	6
Parasitized	HM774283, HM774412, HM774495, HM774274, HM774278, HM774066, HM774740, HM774271, HM774272, HM774276, HM774064, HM774065, HM774192, HM774277, HM774005, HM774728, HM774501, HM774068, HM774624, HM774620, HM774500, HM774410, HM774628, HM774275, HM774282, HM774841, HM773971, HM774729, HM774067, HM774955, HM774503, HM774327, HM774948, HM774006, HM774843, HM774281, HM774147, HM774070, HM774328, HM774326, HM774280, HM774004, HM774730, HM774279, HM774273, HM774739, HM774952, HM774725, HM773975, HM774062, HM774069, HM774331, HM774835	5

Donor condition	GenBank accession numbers	Reference
Immunized with tetanus toxoid	AY866546, AY866548, AY866549, AY866554, AY866556, AY866560, AY866565, AY866567, AY866573, AY866678, AY866583, AY866605, AY866617, AY866623, AY866624, AY866636, AY866641, AY866645, AY866587, AY866659, AY866705, AY866713, AY866717, AY866719, AY866720, AY866721, AY866722, AY866724, AY866725, AY866726, AY866727, AY866728, AY866734, AY866741, AY866742, AY866744, AY866745, AY866746, AY866747, AY866748, AY866752, AY866753, AY866754, AY866755, AY866757, AY866761, AY866765, AY866768, AY866771, AY866773, AY866774, AY866785, AY866787, AY866797, AY866809, AY866814, AY866817	16
Immunized with vaccinia virus	HQ378359, HQ378358, HQ378339, HQ378353, HQ378338, HQ378371, HQ378362, HQ378363, HQ378372, HQ378341, HQ378342, HQ378354, HQ378351, HQ378352, HQ378340, HQ378344, HQ378364, HQ378334, HQ378343, HQ378332, HQ378337, HQ378350, HQ378345, HQ378346, HQ378333, HQ378355, HQ378330, HQ378368, HQ378357, HQ378361, HQ378347, HQ378381, HQ378382, HQ378373, HQ378348, HQ378335, HQ378367, HQ378329, HQ378366, HQ378370, HQ378336, HQ378331, HQ378384, HQ378385, HQ378386, HQ378379, HQ378380, HQ378325, HQ378390, HQ378328, HQ378374, HQ378349, HQ378327, HQ378360, HQ378365, HQ378326, HQ378377, HQ378378, HQ378375, HQ378376, HQ378388, HQ378389, HQ378391, HQ378392, HQ378393, HQ378394, HQ378395, HQ378396, HQ378397, HQ378398, HQ378399, HQ378400, HQ378401, HQ378402, HQ378403, HQ378404, HQ378405, HQ378406, HQ378407, HQ378408, HQ378409, HQ378410, HQ378411, HQ378412, HQ378413	17